Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.13
CVS's Cash to Debt is ranked higher than
54% of the 515 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.50 vs. CVS: 0.13 )
CVS' s 10-Year Cash to Debt Range
Min: 0.06   Max: 1.14
Current: 0.13

0.06
1.14
Equity to Asset 0.53
CVS's Equity to Asset is ranked higher than
82% of the 516 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.42 vs. CVS: 0.53 )
CVS' s 10-Year Equity to Asset Range
Min: 0.39   Max: 0.67
Current: 0.53

0.39
0.67
Interest Coverage 15.55
CVS's Interest Coverage is ranked higher than
69% of the 378 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 13.31 vs. CVS: 15.55 )
CVS' s 10-Year Interest Coverage Range
Min: 3.46   Max: 29.6
Current: 15.55

3.46
29.6
F-Score: 6
Z-Score: 4.54
M-Score: -2.37
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 6.51
CVS's Operating margin (%) is ranked higher than
90% of the 521 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 3.52 vs. CVS: 6.51 )
CVS' s 10-Year Operating margin (%) Range
Min: 3.46   Max: 6.91
Current: 6.51

3.46
6.91
Net-margin (%) 3.70
CVS's Net-margin (%) is ranked higher than
87% of the 521 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.15 vs. CVS: 3.70 )
CVS' s 10-Year Net-margin (%) Range
Min: -5.87   Max: 3.76
Current: 3.7

-5.87
3.76
ROE (%) 12.75
CVS's ROE (%) is ranked higher than
83% of the 512 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 10.04 vs. CVS: 12.75 )
CVS' s 10-Year ROE (%) Range
Min: -29.14   Max: 18.7
Current: 12.75

-29.14
18.7
ROA (%) 6.97
CVS's ROA (%) is ranked higher than
87% of the 521 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 4.12 vs. CVS: 6.97 )
CVS' s 10-Year ROA (%) Range
Min: -13.17   Max: 9.8
Current: 6.97

-13.17
9.8
ROC (Joel Greenblatt) (%) 57.46
CVS's ROC (Joel Greenblatt) (%) is ranked higher than
95% of the 520 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 18.59 vs. CVS: 57.46 )
CVS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 18.78   Max: 55.6
Current: 57.46

18.78
55.6
Revenue Growth (%) 14.10
CVS's Revenue Growth (%) is ranked higher than
92% of the 457 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 4.90 vs. CVS: 14.10 )
CVS' s 10-Year Revenue Growth (%) Range
Min: -13.3   Max: 16
Current: 14.1

-13.3
16
EBITDA Growth (%) 13.60
CVS's EBITDA Growth (%) is ranked higher than
88% of the 419 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 4.00 vs. CVS: 13.60 )
CVS' s 10-Year EBITDA Growth (%) Range
Min: -29.5   Max: 44
Current: 13.6

-29.5
44
EPS Growth (%) 14.60
CVS's EPS Growth (%) is ranked higher than
86% of the 395 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 6.30 vs. CVS: 14.60 )
CVS' s 10-Year EPS Growth (%) Range
Min: -47.5   Max: 109.5
Current: 14.6

-47.5
109.5
» CVS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

CVS Guru Trades in Q3 2013

John Rogers 55,685 sh (New)
Jim Simons 480,305 sh (New)
Ray Dalio 175,050 sh (New)
PRIMECAP Management 371,430 sh (+1668.71%)
Steven Cohen 171,180 sh (+169.24%)
Paul Tudor Jones 10,500 sh (+66.67%)
Joel Greenblatt 44,606 sh (+58.84%)
Jeremy Grantham 2,902,828 sh (+25.83%)
Ruane Cunniff 25,929 sh (+7.34%)
Pioneer Investments 4,312,569 sh (+0.82%)
Wallace Weitz 201,860 sh (+0.33%)
First Pacific Advisors 7,367,300 sh (+0.13%)
Vanguard Health Care Fund 3,335,100 sh (unchged)
Jeff Auxier 98,522 sh (unchged)
Charles de Vaulx 899,866 sh (unchged)
Westport Asset Management 192,090 sh (unchged)
Steven Romick 6,805,000 sh (unchged)
Caxton Associates Sold Out
Mario Gabelli 1,603,542 sh (-0.12%)
Scott Black 186,987 sh (-3.28%)
Chris Davis 36,448,058 sh (-6.3%)
Ken Fisher 147,239 sh (-7.21%)
James Barrow 571,960 sh (-11.31%)
NWQ Managers 3,066,934 sh (-12.8%)
Signature Select Canadian Fund 190,553 sh (-14.72%)
RS Investment Management 614,125 sh (-16.53%)
» More
Q4 2013

CVS Guru Trades in Q4 2013

Bill Frels 6,987 sh (New)
John Rogers 98,420 sh (+76.74%)
PRIMECAP Management 518,630 sh (+39.63%)
Vanguard Health Care Fund 4,388,100 sh (+31.57%)
Jeremy Grantham 3,345,354 sh (+15.24%)
Ken Fisher 158,259 sh (+7.48%)
Pioneer Investments 4,422,362 sh (+2.55%)
First Pacific Advisors 7,451,000 sh (+1.14%)
Westport Asset Management 192,090 sh (unchged)
Steven Romick 6,805,000 sh (unchged)
Charles de Vaulx 899,866 sh (unchged)
Paul Tudor Jones Sold Out
Jim Simons Sold Out
Ray Dalio Sold Out
Jeff Auxier 98,472 sh (-0.05%)
Mario Gabelli 1,600,337 sh (-0.2%)
RS Investment Management 604,025 sh (-1.64%)
Ruane Cunniff 25,454 sh (-1.83%)
Scott Black 180,627 sh (-3.4%)
NWQ Managers 2,958,763 sh (-3.53%)
Chris Davis 33,058,529 sh (-9.3%)
James Barrow 361,095 sh (-36.87%)
Steven Cohen 61,955 sh (-63.81%)
Joel Greenblatt 4,288 sh (-90.39%)
Wallace Weitz 10,000 sh (-95.05%)
» More
Q1 2014

CVS Guru Trades in Q1 2014

Robert Olstein 92,000 sh (New)
Tom Gayner 96,000 sh (New)
PRIMECAP Management 3,221,930 sh (+521.24%)
Joel Greenblatt 7,622 sh (+77.75%)
Ruane Cunniff 27,049 sh (+6.27%)
Pioneer Investments 4,513,000 sh (+2.05%)
Jeff Auxier 98,799 sh (+0.33%)
First Pacific Advisors 7,470,700 sh (+0.26%)
John Rogers 98,420 sh (unchged)
RS Investment Management 604,025 sh (unchged)
Westport Asset Management 192,090 sh (unchged)
Steven Romick 6,805,000 sh (unchged)
Vanguard Health Care Fund 4,388,100 sh (unchged)
Charles de Vaulx 899,866 sh (unchged)
Wallace Weitz Sold Out
Scott Black 178,556 sh (-1.15%)
Steven Cohen 60,850 sh (-1.78%)
Mario Gabelli 1,568,681 sh (-1.98%)
NWQ Managers 2,744,031 sh (-7.26%)
James Barrow 294,395 sh (-18.47%)
Signature Select Canadian Fund 126,053 sh (-33.85%)
Ken Fisher 88,108 sh (-44.33%)
Jeremy Grantham 1,649,081 sh (-50.71%)
Bill Frels 3,367 sh (-51.81%)
Chris Davis 11,435,259 sh (-65.41%)
» More
Q2 2014

CVS Guru Trades in Q2 2014

Manning & Napier Advisors, Inc 133,150 sh (New)
Paul Tudor Jones 5,542 sh (New)
Louis Moore Bacon 5,316 sh (New)
Joel Greenblatt 65,796 sh (+763.24%)
Tom Gayner 197,000 sh (+105.21%)
Ken Fisher 155,365 sh (+76.33%)
James Barrow 348,795 sh (+18.48%)
Bill Frels 3,402 sh (+1.04%)
RS Investment Management 607,225 sh (+0.53%)
First Pacific Advisors 7,497,100 sh (+0.35%)
Robert Olstein 92,000 sh (unchged)
Westport Asset Management 192,090 sh (unchged)
Steven Romick 6,805,000 sh (unchged)
Vanguard Health Care Fund 4,388,100 sh (unchged)
John Rogers 98,420 sh (unchged)
Charles de Vaulx 899,866 sh (unchged)
Caxton Associates 100,000 sh (unchged)
Ruane Cunniff 27,028 sh (-0.08%)
Mario Gabelli 1,563,642 sh (-0.32%)
Jeff Auxier 98,449 sh (-0.35%)
PRIMECAP Management 3,206,070 sh (-0.49%)
Pioneer Investments 4,287,706 sh (-4.99%)
Chris Davis 9,012,151 sh (-21.19%)
NWQ Managers 2,118,767 sh (-22.79%)
Scott Black 126,558 sh (-29.12%)
Jeremy Grantham 109,100 sh (-93.38%)
» More
» Details

Insider Trades

Latest Guru Trades with CVS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Scott Black 2014-06-30 Reduce -29.12%0.41%$72.58 - $78.92 $ 80.67%126558
Tom Gayner 2014-06-30 Add 105.21%0.22%$72.58 - $78.92 $ 80.67%197000
Joel Greenblatt 2014-06-30 Add 763.24%0.05%$72.58 - $78.92 $ 80.67%65796
PRIMECAP Management 2014-03-31 Add 521.24%0.23%$65.44 - $75.3 $ 80.614%3221930
Tom Gayner 2014-03-31 New Buy0.22%$65.44 - $75.3 $ 80.614%96000
Wallace Weitz 2014-03-31 Sold Out 0.02%$65.44 - $75.3 $ 80.614%0
Joel Greenblatt 2014-03-31 Add 77.75%$65.44 - $75.3 $ 80.614%7622
Wallace Weitz 2013-12-31 Reduce -95.05%0.41%$56.64 - $71.58 $ 80.626%10000
Vanguard Health Care Fund 2013-12-31 Add 31.57%0.23%$56.64 - $71.58 $ 80.626%4388100
Ray Dalio 2013-12-31 Sold Out 0.08%$56.64 - $71.58 $ 80.626%0
Joel Greenblatt 2013-12-31 Reduce -90.39%0.07%$56.64 - $71.58 $ 80.626%4288
James Barrow 2013-12-31 Reduce -36.87%0.02%$56.64 - $71.58 $ 80.626%361095
PRIMECAP Management 2013-12-31 Add 39.63%0.01%$56.64 - $71.58 $ 80.626%518630
Ray Dalio 2013-09-30 New Buy0.08%$57.28 - $62.17 $ 80.635%175050
PRIMECAP Management 2013-09-30 Add 1668.71%0.03%$57.28 - $62.17 $ 80.635%371430
Joel Greenblatt 2013-09-30 Add 58.84%0.03%$57.28 - $62.17 $ 80.635%44606
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on CVS Health Corp

Jeff Auxier Comments on CVS - Feb 13, 2014

Healthcare stocks in the Fund had a strong fourth quarter and year. CVS (CVS)’s 26% performance for the quarter is reflective of the fact that 10,000 Americans turn 65 every day and will for the next 15 years. Businesses that are able to serve this growing segment with improving service, innovation, technology, product quality and value should continue to win.



From Jeff Auxier (Trades, Portfolio)'s fourth quarter 2013 commentary.

Check out Jeff Auxier latest stock trades

Top Ranked Articles about CVS Health Corp

The Olstein All Cap Value Fund’s 2014 First Quarter Letter to Shareholders
Dear Fellow Shareholders: Read more...
NEW SITE FEATURE: 10-Year Median Scans
GuruFocus has always delievered the most vast offering of equity research tools available on the market. Last year we introduced the All-In-One Guru Screener. It has been met with immensely positive feedback and has quickly become the go-to scanner for sophisticated investors. Read more...
Jeff Auxier Comments on CVS
Healthcare stocks in the Fund had a strong fourth quarter and year. CVS (CVS)’s 26% performance for the quarter is reflective of the fact that 10,000 Americans turn 65 every day and will for the next 15 years. Businesses that are able to serve this growing segment with improving service, innovation, technology, product quality and value should continue to win. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 19.70
CVS's P/E(ttm) is ranked higher than
78% of the 533 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 21.50 vs. CVS: 19.70 )
CVS' s 10-Year P/E(ttm) Range
Min: 10.57   Max: 25.77
Current: 19.7

10.57
25.77
P/B 2.50
CVS's P/B is ranked higher than
64% of the 533 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.07 vs. CVS: 2.50 )
CVS' s 10-Year P/B Range
Min: 1.01   Max: 3.37
Current: 2.5

1.01
3.37
P/S 0.70
CVS's P/S is ranked higher than
62% of the 533 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.48 vs. CVS: 0.70 )
CVS' s 10-Year P/S Range
Min: 0.4   Max: 0.77
Current: 0.7

0.4
0.77
PFCF 22.70
CVS's PFCF is ranked higher than
87% of the 533 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 141.51 vs. CVS: 22.70 )
CVS' s 10-Year PFCF Range
Min: 7.21   Max: 208.79
Current: 22.7

7.21
208.79
EV-to-EBIT 12.31
CVS's EV-to-EBIT is ranked higher than
82% of the 533 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 15.76 vs. CVS: 12.31 )
CVS' s 10-Year EV-to-EBIT Range
Min: 7.6   Max: 20.4
Current: 12.31

7.6
20.4
PEG 1.84
CVS's PEG is ranked higher than
89% of the 533 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 185.00 vs. CVS: 1.84 )
CVS' s 10-Year PEG Range
Min: 0.55   Max: 7.32
Current: 1.84

0.55
7.32
Shiller P/E 26.00
CVS's Shiller P/E is ranked higher than
82% of the 533 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 34.96 vs. CVS: 26.00 )
CVS' s 10-Year Shiller P/E Range
Min: 13.89   Max: 32.72
Current: 26

13.89
32.72
Current Ratio 1.45
CVS's Current Ratio is ranked higher than
81% of the 517 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.17 vs. CVS: 1.45 )
CVS' s 10-Year Current Ratio Range
Min: 1.05   Max: 2.09
Current: 1.45

1.05
2.09
Quick Ratio 0.77
CVS's Quick Ratio is ranked higher than
74% of the 517 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.68 vs. CVS: 0.77 )
CVS' s 10-Year Quick Ratio Range
Min: 0.2   Max: 0.93
Current: 0.77

0.2
0.93

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.30
CVS's Dividend Yield is ranked lower than
63% of the 445 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.81 vs. CVS: 1.30 )
CVS' s 10-Year Dividend Yield Range
Min: 0.42   Max: 1.47
Current: 1.3

0.42
1.47
Dividend Payout 0.24
CVS's Dividend Payout is ranked higher than
81% of the 533 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.54 vs. CVS: 0.24 )
CVS' s 10-Year Dividend Payout Range
Min: 0.08   Max: 1.87
Current: 0.24

0.08
1.87
Dividend growth (3y) 37.00
CVS's Dividend growth (3y) is ranked higher than
97% of the 359 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 4.50 vs. CVS: 37.00 )
CVS' s 10-Year Dividend growth (3y) Range
Min: -33.8   Max: 37
Current: 37

-33.8
37
Yield on cost (5-Year) 5.23
CVS's Yield on cost (5-Year) is ranked higher than
84% of the 450 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.97 vs. CVS: 5.23 )
CVS' s 10-Year Yield on cost (5-Year) Range
Min: 1.69   Max: 5.91
Current: 5.23

1.69
5.91
Share Buyback Rate 3.80
CVS's Share Buyback Rate is ranked higher than
93% of the 355 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: -0.20 vs. CVS: 3.80 )
CVS' s 10-Year Share Buyback Rate Range
Min: 4.1   Max: -23.2
Current: 3.8

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 1007.50
CVS's Price/Tangible Book is ranked higher than
53% of the 533 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 3.41 vs. CVS: 1007.50 )
CVS' s 10-Year Price/Tangible Book Range
Min: 1.5   Max: 1069.43
Current: 1007.5

1.5
1069.43
Price/DCF (Projected) 1.05
CVS's Price/DCF (Projected) is ranked higher than
89% of the 533 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.49 vs. CVS: 1.05 )
CVS' s 10-Year Price/DCF (Projected) Range
Min: 0.79   Max: 13.56
Current: 1.05

0.79
13.56
Price/Median PS Value 1.23
CVS's Price/Median PS Value is ranked higher than
68% of the 533 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.12 vs. CVS: 1.23 )
CVS' s 10-Year Price/Median PS Value Range
Min: 0.44   Max: 2.52
Current: 1.23

0.44
2.52
Price/Peter Lynch Fair Value 1.50
CVS's Price/Peter Lynch Fair Value is ranked higher than
90% of the 533 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 9999.00 vs. CVS: 1.50 )
CVS' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.62   Max: 3.81
Current: 1.5

0.62
3.81
Price/Graham Number 28.48
CVS's Price/Graham Number is ranked higher than
60% of the 532 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.31 vs. CVS: 28.48 )
CVS' s 10-Year Price/Graham Number Range
Min: 1.13   Max: 29.02
Current: 28.48

1.13
29.02
Earnings Yield (Greenblatt) 8.10
CVS's Earnings Yield (Greenblatt) is ranked higher than
80% of the 498 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 6.70 vs. CVS: 8.10 )
CVS' s 10-Year Earnings Yield (Greenblatt) Range
Min: 4.9   Max: 13.1
Current: 8.1

4.9
13.1
Forward Rate of Return (Yacktman) 16.39
CVS's Forward Rate of Return (Yacktman) is ranked higher than
83% of the 377 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 9.74 vs. CVS: 16.39 )
CVS' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 2.8   Max: 24
Current: 16.39

2.8
24

Business Description

Industry: Retail - Defensive » Pharmaceutical Retailers
Compare:SHDMF, APNHF, GNC, JCOUF, PMC » details
Traded in other countries:CVS.Germany
CVS Caremark Corporation was incorporated in the State of Delaware. The Company is the pharmacy health care provider in the United States. It has three reportable business segments: Pharmacy Services, Retail Pharmacy and Corporate. The Pharmacy Services segment provides a full range of pharmacy benefit management ("PBM") services including mail order pharmacy services, specialty pharmacy services, plan design and administration, formulary management and claims processing. Its clients are primarily employers, insurance companies, unions, government employee groups, managed care organizations and other sponsors of health benefit plans and individuals throughout the United States. In addition, through its SilverScript Insurance Company ("SilverScript") and Accendo Insurance Company ("Accendo") subsidiaries, it is a national provider of drug benefits to eligible beneficiaries under the Federal Government's Medicare Part D program. Currently, the pharmacy services business operates under the Caremark Pharmacy Services, Caremark, CVS Caremark, CarePlus CVS/pharmacy, CarePlus, RxAmerica, AccordantCare and TheraCom names. As of December 31, 2011, the Pharmacy Services segment operated 31 retail specialty pharmacy stores, 12 specialty mail order pharmacies and four mail service pharmacies located in 22 states, the District of Columbia and Puerto Rico. The PBM services involve the design and administration of programs aimed at reducing the cost and improving the safety, effectiveness and convenience of prescription drug use. These Services are Plan Design and Administration, Formulary Management, Discounted Drug Purchase Arrangements, Prescription Management Systems, Mail Pharmacy Program, Specialty Pharmacy, Onsite Pharmacies, Retail Pharmacy Network, Medicare Part D Service, Clinical Services, Disease Management Programs, Quality Assurance and Pharmacogenomic Services. It currently operates multiple information systems platforms to support its Pharmacy Services segment. These information systems incorporate architecture that centralizes the data generated from filling mail service prescriptions, adjudicating retail pharmacy claims and fulfilling other PBM clients' service contracts. It provides pharmaceuticals to eligible members in benefit plans maintained by its clients and utilize its information systems to perform safety checks, drug interaction screening and generic substitution. The Pharmacy Services segment competes with a number of large, national PBM companies, including Medco Health Solutions, Inc. and Express Scripts, Inc., as well as many smaller local or regional PBMs. Its corporate segment provides management and administrative services to support the overall operations of the Company. The Corporate segment consists of certain aspects of its executive management, corporate relations, legal, compliance, human resources, and corporate information technology and finance departments.
» More Articles for CVS

Headlines

Articles On GuruFocus.com
WalMart Diversifies Into Medi-Care Sep 17 2014 
These 6 Top Dividend Stocks Starting To Take Off Sep 09 2014 
Markel CIO Tom Gayner Buys Deere, Unilever, Chubb, Sells Capital One Financial, Chevron, Loews Aug 12 2014 
Weekly CFO Sells Highlight: Equity Residential, Affiliated Managers Group Inc, CVS Caremark Corp. Aug 10 2014 
Is Walgreen Set For A Better 2014? Jul 28 2014 
Realty Income: Another BORING and Solid Quarter for the Monthly Dividend Company Jul 24 2014 
The Olstein All Cap Value Fund’s 2014 First Quarter Letter to Shareholders Jul 22 2014 
Steven Romick's Top Five Stocks Jul 11 2014 
NEW SITE FEATURE: 10-Year Median Scans May 21 2014 
Rite Aid Corporation May Be a Buy: More Upside Expected May 20 2014 

More From Our Partners
CVS Health Corp Outperforms Key Peers In 2014 Sep 22 2014 - BENZINGA
CVS Health Corp Shares Strongest Performer In Drug Retail Space Sep 22 2014 - BENZINGA
S&P 500 Gives Up 2,000 On Volume Sep 22 2014 - BENZINGA

More From Other Websites
Early Glance: Drugstore companies Sep 23 2014
Final Glance: Drugstore companies Sep 22 2014
CVS Health Corp Outperforms Key Peers In 2014 Sep 22 2014
Which Medicare Drug Plans To Be Less Costly In 2015? Sep 22 2014
Why Walgreen's EPS May Have Less Upside Than Before Sep 22 2014
Shutterfly May Be Attracting More Suitors; Shares Fly Sep 22 2014
Midday Glance: Drugstore companies Sep 22 2014
CVS Health's MinuteClinic Debuts in St. Louis at 5 Stores (revised) Sep 22 2014
MinuteClinic Walk-in Medical Clinics Opening in Memphis Sep 19 2014
CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in... Sep 19 2014
The Outcome of Scotland's Vote, Fed's Action Sep 18 2014
Rite Aid Dives On Generic Drug Reimbursement Warning Sep 18 2014
Gilead Down on Weak Simtuzumab Data and Sovaldi News Sep 18 2014
Rite Aid cuts profit forecast as medications come off patent Sep 18 2014
US Drugstores: Bitter pill to swallow Sep 18 2014
Peabody sinks after Goldman downgrade Sep 18 2014
Cramer's Mad Dash: Rite Aid guidance horrendous Sep 18 2014
[video] Cramer's Mad Dash: Rite Aid guidance horrendous Sep 18 2014
[video] Oracle and Rite Aid Set to Report Earnings, Cramer on Kinder Sep 18 2014
CVS: One In 12 Hepatitis C Patients Not Adhering To $1,000/Day Pill Sep 17 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK